Elanco Australasia Pty Ltd v Abbey Laboratories Pty Ltd [2024] FCA 640
Elanco Sheepish as Patent Application Not Inventive
read more
100% of Pearce IP Executives and Special Counsel ranked in WIPR Leaders 2024
WIPR Leaders released its annual global guide to the world’s leading practitioners last week, and we are delighted to have 10 Pearce IP leaders across Australia and New Zealand...
Pearce IP BioBlast for w/e 05 July 2024
7 July 2024 | IN | Approval Alert: Zydus Life Sciences’ Biosimilar Nivolumab Approved in IndiaOn 7 July 2024, Medical Dialogues reported that Zydus Life Sciences’ biosimilar...
Seasoned Patent Attorney Rosie Stramandinoli joins Pearce IP as Special Counsel
We are thrilled to welcome Rosie Stramandinoli as Pearce IP’s Special Counsel, Patent & Trade Mark Attorney (AU, NZ). Rosie joins Pearce IP with more than 30 years’ experience at the highest levels of private practice at one of Australia’s leading IP firms and in-house. This, combined with her background in chemistry and business, makes Rosie a perfect fit for Pearce IP’s life sciences clients.
Pearce IP ranked by MIP for Patent Prosecution with 70% of its patent professionals
We are thrilled to announce that Pearce IP has been honoured as Australasian Lawyer’s 2024 The Best Boutique Intellectual Property Law Firms in Australia!
Pearce IP BioBlast for fortnight ending 28 June 2024
28 June 2024 | Shanghai Henlius Biotech Completes Phase 1 Trials for Daratumumab Biosimilar Shanghai Henlius Biotech has announced the completion of phase 1 clinical trials of...
Pearce IP is Australasian Lawyer’s 2024 Top Boutique Firm
We are thrilled to announce that Pearce IP has been honoured as Australasian Lawyer’s 2024 The Best Boutique Intellectual Property Law Firms in Australia!
Patenting Life Sciences Technologies
How claim types can influence enforcement strategies
How claim types and form will influence enforcement strategies
Patent Opposition Fails to Block Patent Term Extension for COPD and Asthma Drug
CQMS Triumphs in Patent Opposition Against ESCO Group
Pearce IP BioBlast for fortnight ending 14 June 2024
14 June 2024 | AU | Approval Alert: Bayer’s High Dose Eylea® (aflibercept) Approved in Australia On 14 June 2024, Australia’s Therapeutic Goods Administration (TGA) approved...
Don’t Dig Your Own Hole – Broad Claims and a Deficient Disclosure Can Lead to Support, Sufficiency and Utility Issues
CQMS Triumphs in Patent Opposition Against ESCO Group
8 Honours for Pearce IP and its Leaders in IAM Patent 1000 Guide
We are proud to announce that two of Pearce IP’s Leaders, Adele Chadwick and Chris Vindurampulle, have been honoured by WIPR Diversity Top 100 2024.
More than 70% of Pearce IP Patent Professionals Honoured in MIP’s IP Stars Guide
We are proud to announce that two of Pearce IP’s Leaders, Adele Chadwick and Chris Vindurampulle, have been honoured by WIPR Diversity Top 100 2024.
Pearce IP BioBlast w/e 31 May 2024
31 May 2024 | EU | US | Europe’s CHMP Recommends Dupixent® (Dupilumab) as COPD Add-On Treatment On 31 May 2024, Regeneron and Sanofi announced that the Committee for Medicinal...
Carpark Saga Reaches Finale
SARB Management Group Pty Ltd trading as Database Consultants Australia v Vehicle Monitoring Systems Pty Limited (No 2) [2024] FCAFC 53
Pearce IP BioBlast w/e 24 May 2024
24 MAY 2024 | EU | Shanghai Henlius’ & Organon’s Biosimilar Denosumab Applications Validated by EMA On 24 May 2024, Shanghai Henlius and Organon announced that the European...
Pearce IP BioBlast w/e 17 May 2024
17 MAY 2024 | KR | New Indication Alert: MSD’s Keytruda® (Pembrolizumab) Approved in Korea for New NSCLC and Cervical Cancer Indications On 16 and 17 May 2024, respectively, the...
Leading IP Litigator Paul Johns joins Pearce IP signalling further growth in New Zealand
Pearce IP’s New Zealand Expansion Fueled by Commencement of Pre-Eminent IP Litigator Paul Johns from AJ Park
Navigating Post-Grant Patent Amendments: Lessons from R F Industries v Mine Site Technologies
R F Industries Pty Ltd v Mine Site Technologies Pty Ltd [2024] APO 16 provides a good example of the usefulness of re-examination and opposition to challenge a granted patent.
Pearce IP BioBlast w/e 10 May 2024
10 MAY 2024 | US | Valorum Biologics to Launch Xbrane and Stada’s Ranibizumab Biosimilar in the US On 10 May 2024, Xbrane and Stada announced the exclusive licensing agreement...
Pearce IP’s Adele Chadwick and Chris Vindurampulle Honoured in WIPR Diversity’s Top 100 2024
We are proud to announce that two of Pearce IP’s Leaders, Adele Chadwick and Chris Vindurampulle, have been honoured by WIPR Diversity Top 100 2024.
Pearce IP BioBlast w/e 03 May 2024
03 MAY 2024 | CA | Lupin & Sandoz Launch Rymti® (etanercept) Biosimilar in Canada On 3 May 2024, Indian-headquartered Lupin, in partnership with Sandoz, announced its...
How’s Your Hamstring?
Vald Pty Ltd sued KangaTech Pty Ltd for patent infringement and Kanga cross-claimed alleging that Vald’s patent is invalid on the basis of lack of support, lack of sufficiency and lack of inventive step.
Zoetis Vaccine Patents’ Last Stand
Justice Rofe has delivered a further supplementary decision in the dispute between Boehringer Ingelheim Animal Health USA Inc (Boehringer) and Zoetis Services LLC (Zoetis) in relation to three Zoetis vaccine patent applications. Her Honour has now held the last remaining valid claim to be invalid for failure to disclose the best method of performing the claimed invention.
Recent BioBlast® Updates
Get our Pearce IP Blogs & BioBlast® sent directly to your inbox
Subscribe to our Pearce IP Blogs and BioBlast® to receive our updates via email.